CLEC4C and CD4+/CD56+ hematodermic neoplasm: Both <i>in vitro</i> and <i>in vivo</i> studies demonstrated the potent antitumor activity of CliniMACS Prodigy-manufactured BDCA2 CAR NK cells, highlighting a promising treatment strategy for BPDCN.